The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.

1,25-Dihydroxyvitamin D (1,25-(OH)2D3) directly suppresses the secretion and synthesis of PTH in vivo and in cell culture. This compound has been used to treat secondary hyperparathyroidism associated with renal failure, but in some patients prolonged treatment with 1,25-(OH)2D3 results in hypercalc...

Cur síos iomlán

Sábháilte in:

Sonraí bibleagrafaíochta
Foilsithe in:	J Clin Invest
Príomhchruthaitheoirí:	Brown, A J, Ritter, C R, Finch, J L, Morrissey, J, Martin, K J, Murayama, E, Nishii, Y, Slatopolsky, E
Formáid:	Artigo
Teanga:	Inglês
Foilsithe / Cruthaithe:	American Society for Clinical Investigation 1989
Ábhair:	Research Article
Rochtain ar líne:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC329712/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/2760211/ https://ncbi.nlm.nih.govhttps://doi.org/10.1172/JCI114229
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.

Míreanna comhchosúla